Search Results - "Manos, Michael P"

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade by Gu, Shengqing Stan, Zhang, Wubing, Wang, Xiaoqing, Jiang, Peng, Traugh, Nicole, Li, Ziyi, Meyer, Clifford, Stewig, Blair, Xie, Yingtian, Bu, Xia, Manos, Michael P, Font-Tello, Alba, Gjini, Evisa, Lako, Ana, Lim, Klothilda, Conway, Jake, Tewari, Alok K, Zeng, Zexian, Sahu, Avinash Das, Tokheim, Collin, Weirather, Jason L, Fu, Jingxin, Zhang, Yi, Kroger, Benjamin, Liang, Jin Hua, Cejas, Paloma, Freeman, Gordon J, Rodig, Scott, Long, Henry W, Gewurz, Benjamin E, Hodi, F Stephen, Brown, Myles, Liu, X Shirley

“…Immune checkpoint blockade (ICB) therapy revolutionized cancer treatment, but many patients with impaired MHC-I expression remain refractory. Here, we combined…”
Get more information

Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade by Gstalder, Cécile, Liu, David, Miao, Diana, Lutterbach, Bart, DeVine, Alexander L, Lin, Chenyu, Shettigar, Megha, Pancholi, Priya, Buchbinder, Elizabeth I, Carter, Scott L, Manos, Michael P, Rojas-Rudilla, Vanesa, Brennick, Ryan, Gjini, Evisa, Chen, Pei-Hsuan, Lako, Ana, Rodig, Scott, Yoon, Charles H, Freeman, Gordon J, Barbie, David A, Hodi, F Stephen, Miles, Wayne, Van Allen, Eliezer M, Haq, Rizwan

“…The molecular mechanisms leading to resistance to PD-1 blockade are largely unknown. Here, we characterize tumor biopsies from a patient with melanoma who…”
Get more information

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy by Wu, Xinqi, Giobbie-Hurder, Anita, Liao, Xiaoyun, Connelly, Courtney, Connolly, Erin M, Li, Jingjing, Manos, Michael P, Lawrence, Donald, McDermott, David, Severgnini, Mariano, Zhou, Jun, Gjini, Evisa, Lako, Ana, Lipschitz, Mikel, Pak, Christine J, Abdelrahman, Sara, Rodig, Scott, Hodi, F Stephen

“…Immune checkpoint therapies targeting CTLA-4 and PD-1 have proven effective in cancer treatment. However, the identification of biomarkers for predicting…”
Get more information

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade by Miller, Peter G, Sperling, Adam S, Gibson, Christopher J, Pozdnyakova, Olga, Wong, Waihay J, Manos, Michael P, Buchbinder, Elizabeth I, Hodi, F Stephen, Ebert, Benjamin L, Davids, Matthew S

Get full text

Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases by Wei, Alexander Z., Uriel, Matan, Porcu, Agata, Manos, Michael P., Mercurio, Ann C., Caplan, Michael M., Hulse, Liam, Seedor, Rino S., Holovatska, Marta, Francis, Jasmine, Khan, Shaheer A., McDonnell, Diana E., Bogomolny, Dmitry, Sato, Takami, Marr, Brian P., Haq, Rizwan, Orloff, Marlana, Shoushtari, Alexander, Carvajal, Richard D.

“…Metastatic uveal melanoma (mUM) is an advanced ocular malignancy characterized by a hepatotropic pattern of spread. As the incidence of brain metastases (BM)…”
Get full text

Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors by Bui, Ai-Tram N, Tyan, Kevin, Giobbie-Hurder, Anita, Klein, Isaac A, Manos, Michael P, Zubiri, Leyre, Reynolds, Kerry, Grover, Shilpa, Weinhouse, Gerald L, Ott, Patrick A, LeBoeuf, Nicole R, Rahma, Osama

“…To evaluate the impact of Sars-Cov-2 infection on mortality and immune checkpoint inhibitor (ICI) toxicity in patients with cancer receiving ICIs compared to…”
Get full text

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade by Zhou, Jun, Mahoney, Kathleen M, Giobbie-Hurder, Anita, Zhao, Fengmin, Lee, Sandra, Liao, Xiaoyun, Rodig, Scott, Li, Jingjing, Wu, Xinqi, Butterfield, Lisa H, Piesche, Matthias, Manos, Michael P, Eastman, Lauren M, Dranoff, Glenn, Freeman, Gordon J, Hodi, F Stephen

“…Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in…”
Get more information

Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors by Burger, Megan L., Cruz, Amanda M., Crossland, Grace E., Gaglia, Giorgio, Ritch, Cecily C., Blatt, Sarah E., Bhutkar, Arjun, Canner, David, Kienka, Tamina, Tavana, Sara Z., Barandiaran, Alexia L., Garmilla, Andrea, Schenkel, Jason M., Hillman, Michelle, de los Rios Kobara, Izumi, Li, Amy, Jaeger, Alex M., Hwang, William L., Westcott, Peter M.K., Manos, Michael P., Holovatska, Marta M., Hodi, F. Stephen, Regev, Aviv, Santagata, Sandro, Jacks, Tyler

“…CD8 T cell responses against different tumor neoantigens occur simultaneously, yet little is known about the interplay between responses and its impact on…”
Get full text

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy by Bai, Xue, Hu, Jiani, Betof Warner, Allison, Quach, Henry T, Cann, Christopher G, Zhang, Michael Z, Si, Lu, Tang, Bixia, Cui, Chuanliang, Yang, Xiaoling, Wei, Xiaoting, Pallan, Lalit, Harvey, Catriona, Manos, Michael P, Ouyang, Olivia, Kim, Michelle S, Kasumova, Gyulnara, Cohen, Justine V, Lawrence, Donald P, Freedman, Christine, Fadden, Riley M, Rubin, Krista M, Sharova, Tatyana, Frederick, Dennie T, Flaherty, Keith T, Rahma, Osama E, Long, Georgina V, Menzies, Alexander M, Guo, Jun, Shoushtari, Alexander N, Johnson, Douglas B, Sullivan, Ryan J, Boland, Genevieve M

“…Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require…”
Get full text

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions by Nishino, Mizuki, Giobbie-Hurder, Anita, Manos, Michael P, Bailey, Nancy, Buchbinder, Elizabeth I, Ott, Patrick A, Ramaiya, Nikhil H, Hodi, F Stephen

“…Characterize tumor burden dynamics during PD-1 inhibitor therapy and investigate the association with overall survival (OS) in advanced melanoma. The study…”
Get full text

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade by Tabasum, Saba, Thapa, Dinesh, Giobbie-Hurder, Anita, Weirather, Jason L, Campisi, Marco, Schol, Pieter J, Li, Xiaoyu, Li, Jingjing, Yoon, Charles H, Manos, Michael P, Barbie, David A, Hodi, F Stephen

“…Immune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve…”
Get more information

Long-term Overall Survival and Predictors in Anti–PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study by Naik, Girish S., Buchbinder, Elizabeth I., Cohen, Justine V., Manos, Michael P., Johnson, Alistair E.W., Bowling, Peter, Aizer, Ayal A., Schoenfeld, Jonathan D., Lawrence, Donald P., Haq, Rizwan, Hodi, Frank Stephen, Sullivan, Ryan J., Ott, Patrick A.

“…Long-term survival outcomes among melanoma patients with brain metastases treated with immune checkpoint inhibitors are limited. In this retrospective study at…”
Get full text

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade by Zhou, Jun, Li, Jingjing, Guleria, Indira, Chen, Tianqi, Giobbie-Hurder, Anita, Stevens, Jonathan, Gupta, Meghna, Wu, Xinqi, Brennick, Ryan C., Manos, Michael P., Hodi, F. Stephen

“…Expression of inhibitors of apoptosis protein (IAP) family members is associated with poor prognosis in cancer patients. Immunity to ML-IAP (livin) and…”
Get full text

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit by Barroso-Sousa, Romualdo, Forman, Juliet, Collier, Katharine, Weber, Zachary T, Jammihal, Tejas R, Kao, Katrina Z, Richardson, 3rd, Edward T, Keenan, Tanya, Cohen, Ofir, Manos, Michael P, Brennick, Ryan C, Ott, Patrick A, Hodi, F Stephen, Dillon, Deborah A, Attaya, Victoria, O'Meara, Tess, Lin, Nancy U, Van Allen, Eliezer M, Rodig, Scott, Winer, Eric P, Mittendorf, Elizabeth A, Wu, Catherine J, Wagle, Nikhil, Stover, Daniel G, Shukla, Sachet A, Tolaney, Sara M

“…In metastatic triple-negative breast cancer (mTNBC), consistent biomarkers of immune checkpoint inhibitor (ICI) therapy benefit remain elusive. We evaluated…”
Get more information

Risks for Venous Thromboembolism with Immune Checkpoint Inhibitor Therapy by Connors, Jean M., Sussman, Tamara A, Dryg, Ian D, Giobbe-Hurder, Anita, Manos, Michael P, Weirather, Jason L., Hodi, Stephen

“…Background: Immune checkpoint inhibitor therapy (ICI) has been variably associated with increased risk of VTE, with some reports suggesting increased risk and…”
Get full text

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma by Khaddour, Karam, Haq, Rizwan, Buchbinder, Elizabeth I, Liu, David, Manos, Michael P, Ott, Patrick A, Hodi, F Stephen, Insco, Megan L

“…Abstract The biological and clinical relevance of gene fusions in melanoma is unknown. Reports and preclinical data have suggested that tumor cells with…”
Get full text

Leveraging longitudinal clinical annotations and panel sequencing to characterize dynamics of organotropism in metastatic melanoma by Aprati, Tyler J, Manos, Michael P., Ge, Will, Tarantino, Giuseppe, Bai, Xue, Rahma, Osama E., Gusev, Alexander, Boland, Genevieve Marie, Kehl, Kenneth L., Liu, David

“…9526 Background: Although metastasis plays a major role in the mortality and morbidity of melanoma, patterns of metastasis and drivers of organotropism have…”
Get full text

Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial by Buchbinder, Elizabeth Iannotti, Song, Zihe, Lee, Sandra J., Keefe, Kimberly W., Manos, Michael P., Tarhini, Ahmad A., Dougan, Michael L., Cohen, Justine Vanessa

“…12013 Background: Immunotherapy with immune checkpoint inhibition (ICI) is being widely adopted in the treatment of patients with a wide range of malignancies…”
Get full text

Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy by Buchbinder, Elizabeth Iannotti, Pfaff, Kathleen L., Manos, Michael P., Ouyang, Olivia, Ott, Patrick Alexander, Rodig, Scott J., Hodi, F. Stephen

“…Abstract only 9567 Background: As immunotherapy with checkpoint blockade becomes the backbone of melanoma treatment there is a need to better understand the…”
Get full text

Is radiation necrosis in radiated melanoma brain metastasis increasing because immunotherapy is contributing to this or are patients just living longer? by Buchbinder, Elizabeth Iannotti, Shi, Diana D., Pfaff, Kathleen L., Manos, Michael P., Ouyang, Olivia, Liu, David, Rodig, Scott J., Aizer, Ayal

“…Abstract only e21518 Background: The use of immune checkpoint inhibitors, particularly combination ipilimumab and nivolumab, has drastically changed the…”
Get full text